Holen Sie sich die Stockscreener-App
12.08
0.25%
-0.03
Vorhandelsmarkt:
11.77
-0.31
-2.57%
Schlusskurs vom Vortag:
$12.11
Offen:
$12.19
24-Stunden-Volumen:
350.93K
Relative Volume:
0.87
Marktkapitalisierung:
$657.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-5.88%
1M Leistung:
-31.32%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.69
$12.48
1-Wochen-Bereich:
$11.56
$13.96
52-Wochen-Spanne:
$11.56
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-785-8308
Adresse
245 MAIN STREET, CAMBRIDGE
Vergleichen Sie BCAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
12.08 | 657.34M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Barclays PLC Purchases Shares of 10,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Initiates Corporate Presentation on Promising Corporate Strategy - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 4.1%Here's What Happened - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowHere's What Happened - MarketBeat
Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Geode Capital Management LLC Buys Shares of 48,639 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Geode Capital Management LLC Takes $1.24 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Jane Street Group LLC Makes New $309,000 Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing - Reuters
Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year LowWhat's Next? - MarketBeat
Barclays PLC Takes $255,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 2.9%What's Next? - MarketBeat
Biotech IPO Shares 2025 Climb In Trading Debuts After Deals Upsized - Browvopetshop
Bicara’s era? Merus, ALX also active in head and neck cancer - BioWorld Online
Most important biotech stories of 2024: IPOs, M&A deals and more layoffs - The Business Journals
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.00 Average PT from Analysts - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.9%What's Next? - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Buy" by Analysts - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Trading 5.5% HigherStill a Buy? - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Should You Sell? - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownTime to Sell? - MarketBeat
This cancer drug developer held the Bay State's largest IPO of 2024 - The Business Journals
Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year LowWhat's Next? - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.8%Time to Sell? - MarketBeat
The Manufacturers Life Insurance Company Takes $582,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
763,943 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Wellington Management Group LLP - MarketBeat
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Point72 Asset Management L.P. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Now Covered by HC Wainwright - MarketBeat
Janus Henderson Group PLC Buys New Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
31,780 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Walleye Capital LLC - MarketBeat
2,273,792 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Fmr LLC - MarketBeat
HC Wainwright & Co. Initiates Coverage of Bicara Therapeutics (BCAX) with Buy Recommendation - MSN
Maven Securities LTD Buys Shares of 50,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
35,000 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Samsara BioCapital LLC - MarketBeat
RA Capital Management L.P. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Point72 DIFC Ltd Takes $1.42 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Baker BROS. Advisors LP Makes New $21.23 Million Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Braidwell LP Makes New $42.22 Million Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Vestal Point Capital LP Acquires Shares of 425,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
First Turn Management LLC Takes $14.32 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World
FY2024 EPS Estimates for BCAX Reduced by Cantor Fitzgerald - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2%Here's Why - MarketBeat
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Es liegen keine Finanzdaten für Bicara Therapeutics Inc (BCAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):